Loading...
XSHE300086
Market cap321mUSD
Dec 27, Last price  
5.15CNY
1D
4.46%
1Q
19.21%
Jan 2017
-63.00%
IPO
-62.79%
Name

Honz Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300086 chart
P/E
203.29
P/S
3.17
EPS
0.03
Div Yield, %
1.04%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
-3.48%
Revenues
740m
+38.05%
95,940,150135,846,194218,779,083314,451,808304,241,891368,780,279309,337,001408,538,464409,757,276471,474,596480,831,720882,744,8031,008,431,482921,642,902836,565,805535,745,365739,569,815
Net income
12m
34,197,59049,524,79297,577,158139,317,546022,580,53314,852,93562,092,44668,311,10546,156,62550,196,88613,366,21809,339,25210,987,504011,529,863
CFO
71m
+141.09%
30,589,23862,607,03893,576,12879,893,9720109,459,62678,928,79873,930,32278,297,41590,883,87118,172,221157,658,19145,059,857011,329,33629,322,90570,693,705
Dividend
Aug 13, 20210.02 CNY/sh

Profile

Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pediatric medicines in China. It offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine. The company markets its products through a network of agents and sales terminals. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. is headquartered in Guangzhou, China.
URL
http://www.honz.com.cn
IPO date
May 26, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
739,570
38.05%
535,745
-35.96%
836,566
-9.23%
Cost of revenue
570,956
581,752
747,578
Unusual Expense (Income)
NOPBT
168,614
(46,006)
88,988
NOPBT Margin
22.80%
10.64%
Operating Taxes
18,277
9,783
Tax Rate
10.84%
10.99%
NOPAT
150,337
(46,006)
79,205
Net income
11,530
 
10,988
17.65%
Dividends
(24,344)
Dividend yield
0.92%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
176,661
240,272
249,281
Long-term debt
324,978
342,846
343,517
Deferred revenue
48,179
51,002
35,608
Other long-term liabilities
1
1
Net debt
351,941
31,892
35,288
Cash flow
Cash from operating activities
70,694
29,323
11,329
CAPEX
(137,559)
Cash from investing activities
(59,478)
13,382
90,915
Cash from financing activities
(131,789)
FCF
(43,240)
82,635
(38,218)
Balance
Cash
144,398
269,812
258,553
Long term investments
5,300
281,413
298,957
Excess cash
112,720
524,438
515,682
Stockholders' equity
483,264
596,116
736,175
Invested Capital
1,815,122
1,440,198
1,640,747
ROIC
9.24%
4.65%
ROCE
8.60%
4.05%
EV
Common stock shares outstanding
450,385
450,000
450,000
Price
5.87
-5.63%
6.22
-28.34%
8.68
54.45%
Market cap
2,643,762
-5.55%
2,799,000
-28.34%
3,906,000
54.45%
EV
3,028,967
2,870,218
3,990,981
EBITDA
246,039
4,239
133,646
EV/EBITDA
12.31
677.13
29.86
Interest
25,405
27,400
18,737
Interest/NOPBT
15.07%
21.06%